Kaftrio 60 mg/40 mg/80 mg and 75 mg/50 mg/100 mg granules in sachet
*Company:
Vertex Pharmaceuticals (Ireland) LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company

Updated on 10 April 2025
File name
emea-GRANULES-PIL-en-IRL.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 10 April 2025
File name
emea-GRANULES-SmPC-en-IRL.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 02 April 2025
File name
emea - Granules - SmPC - en- IRL.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Update to 4.4 Special warnings and precautions for use - Rash events
Rash events typically occur during the first month of therapy. Most events were mild to moderate in severity and in rare cases, rash was associated with additional symptoms such as fever or facial swelling. In the majority of cases, administration of IVA/TEZ/ELX was continued and the rash resolved without treatment. Children have a higher incidence rate compared to adults. The incidence of rash events was also higher in females compared to males, particularly in females taking hormonal contraceptives (see section 4.8). A role for hormonal contraceptives in the occurrence of rash cannot be excluded. For patients taking hormonal contraceptives who develop rash, interrupting treatment with IVA/TEZ/ELX in combination with IVA and hormonal contraceptives should be considered. Following the resolution of rash, it should be considered if resuming IVA/TEZ/ELX in combination with IVA without hormonal contraceptives is appropriate. If rash does not recur, resumption of hormonal contraceptives can be considered (see section 4.8).
Update to 4.6 Fertility, pregnancy and lactation - Breast-feeding
Limited data show that ELX, TEZ, and IVA are excreted in human milk and have been quantified in plasma of breastfed newborns/infants of treated women. There is insufficient information on the effects of IVA/TEZ/ELX in newborns/infants. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from IVA/TEZ/ELX therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Update to 4.8 Undesirable effects Table 4 Adverse reactions
Immune system disorders - Hypersensitivity - not known
Rash events
Studies in IVA/TEZ/ELX-treated patients above 12 years of age showed an incidence of rash events (e.g., rash, rash pruritic) of 10.9% (study 445-102) compared to 6.5% in placebo‑treated patients. The paediatric population showed a higher incidence rate (see section Paediatric population for further details). The incidence of rash events by patient sex was 5.8% in males and 16.3% in females in IVA/TEZ/ELX-treated patients and 4.8% in males and 8.3% in females in placebo-treated patients. In patients treated with IVA/TEZ/ELX, the incidence of rash events was 20.5% in females taking hormonal contraceptive and 13.6% in females not taking hormonal contraceptive (see section 4.4).
Overall, rash events typically occur during the first month of therapy. Most events were mild to moderate in severity, and in rare cases, rash was associated with additional symptoms such as fever or facial swelling. In the majority of cases, administration of IVA/TEZ/ELX was continued and the rash resolved without treatment.
Rash
While studies in patients above 12 years of age showed an incidence rate of 10.9% (study 445-102), patients between 6 and 11 years of age had an incidence rate of 24.2% (study 445-106). During study 445-111 in patients aged 2 to less than 6 years, 15 (20.0%) subjects had at least 1 rash event, 4 (9.8%) females and 11 (32.4%) males.
Updated on 02 April 2025
File name
emea - Granules - PIL - en- IRL.pdf
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Update to Possible side effects to add - Rash (more common in children, and in women compared to men) and Allergic reactions (hypersensitivity)
Updated on 21 November 2024
File name
Kaftrio Granules PIL.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 03 May 2024
File name
Kaftrio SPC Granules Ireland 30Apr24.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 03 May 2024
File name
Kaftrio PIL Granules Ireland 30Apr24.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 14 March 2024
File name
Kaftrio EU Granules Ireland SPC 16Feb2024.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 14 March 2024
File name
Kaftrio EU Granules Ireland PIL 19Feb2024.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
- Correction of spelling/typing errors
Updated on 04 December 2023
File name
Kaftrio EU Granules Ireland SPC 22Nov23.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 04 December 2023
File name
Kaftrio EU Granules Ireland PIL 22Nov23.pdf
Reasons for updating
- New PIL for new product
Vertex Pharmaceuticals (Ireland) Limited
 Limited.webp)
Address:
Vertex Pharmaceuticals (Ireland) Limited, Unit 49, Block 5, Northwood Court, Northwood Crescent, Dublin 9, D09 T665, IrelandMedical Information E-mail:
vertexmedicalinfo@vrtx.comTelephone:
+353 (1) 7617299Fax:
+44 (0)20 3204 5220Medical Information Facsimile:
+44 (0)1235 438 190Medical Information Direct Line:
1800 924568Customer Care direct line:
1800924568